PEPTIDREAM INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,596 JPY | -1.08% |
|
+7.04% | +7.33% |
| Sales 2024 * | 34.39B 221M | Sales 2025 * | 38.78B 249M | Capitalization | 207B 1.33B |
|---|---|---|---|---|---|
| Net income 2024 * | 7.03B 45.22M | Net income 2025 * | 9.13B 58.68M | EV / Sales 2024 * | 5.71 x |
| Net cash position 2024 * | 10.43B 67.06M | Net cash position 2025 * | 21B 135M | EV / Sales 2025 * | 4.79 x |
| P/E ratio 2024 * |
29.4
x | P/E ratio 2025 * |
22.7
x | Employees | 603 |
| Yield 2024 * |
-
| Yield 2025 * |
0.13% | Free-Float | 73.93% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -1.08% | ||
| 1 week | +7.04% | ||
| Current month | +12.08% | ||
| 1 month | +12.20% | ||
| 3 months | +18.23% | ||
| 6 months | +24.70% | ||
| Current year | +7.33% |
1 week
1 431.00
1 650.50
1 month
1 378.501 650.50
Current year
1 224.501 650.50
1 year
1 039.002 549.00
3 years
1 039.005 560.00
5 years
1 039.006 540.00
10 years
646.256 540.00
| Managers | Title | Age | Since |
|---|---|---|---|
Patrick Reid
CEO | Chief Executive Officer | 49 | 06-12-31 |
| Director of Finance/CFO | 46 | 17-12-31 | |
Keiichi Masuya
COO | Chief Operating Officer | 55 | 14-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Patrick Reid
CEO | Chief Executive Officer | 49 | 06-12-31 |
Michio Sasaoka
BRD | Director/Board Member | 74 | 12-04-30 |
Junko Morita
BRD | Director/Board Member | 52 | 21-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.03% | 16 M€ | -7.62% | ||
| 0.54% | 15 M€ | +5.53% | ||
| 0.06% | 14 M€ | +15.63% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 1,596 | -1.08% | 828 200 |
| 24-04-24 | 1,613 | -0.55% | 1,043,200 |
| 24-04-23 | 1,622 | +6.89% | 1,230,200 |
| 24-04-22 | 1,518 | +3.34% | 449,900 |
| 24-04-19 | 1,468 | -3.29% | 881,300 |
Delayed Quote Japan Exchange, April 25, 2024 at 02:00 am EDT
More quotes
PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).
Calendar
2024-05-13
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1,613
JPY
Average target price
2,667
JPY
Spread / Average Target
+65.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.33% | 1.35B | |
| -3.04% | 104B | |
| +1.04% | 97.42B | |
| +0.79% | 22.2B | |
| -18.05% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -16.14% | 15.06B | |
| +4.12% | 13.98B | |
| +30.67% | 11.66B |
- Stock Market
- Equities
- 4587 Stock
